This is admittedly unscientific, but it seems intuitively unlikely that a small-molecule drug added to a checkpoint inhibitor is going to be the Holy Grail in the treatment of metastatic cancers. I think this is one reason NKTR-214 is generating more excitement than, say, Epacadostat.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.